SCHEMBL20876244

SCHEMBL20876244

CC1(c2ccccc2)COc2ccc(C(=O)O)cc21

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 6/20 0.52
RARB P10826 6/20 0.50
RARG P13631 6/20 0.50
RARA P10276 5/20 0.50
BRD2 P25440 1/20 0.45
BRD3 Q15059 1/20 0.45
BRDT Q58F21 1/20 0.45
CNR2 P34972 1/20 0.45
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.41
ALOX5 P09917 1/20 0.41
RXRA P19793 2/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
TSHR P16473 1/20 0.40
CYP26A1 O43174 1/20 0.39
CYP26B1 Q9NR63 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7802938 0.88 RARA (0.48) BRD4RARBRARGRARACNR2
SCHEMBL20887637 0.87 RARB (0.52) BRD4RARBRARGRARABRD2
SCHEMBL29595859 0.87 RARB (0.52) BRD4RARBRARGRARABRD2
SCHEMBL6730217 0.82 RXRA (0.57) RARBRARGRARARXRACYP26A1
SCHEMBL3542625 0.80 RARB (0.71) RARBRARGRARACNR2ALDH1A1
SCHEMBL20876234 0.80 BRD4 (0.48) BRD4RARBRARGRARACNR2
SCHEMBL7800004 0.79 RXRA (0.47) RARBRARGRARARXRACYP26A1
Hydrochloric Acid SCHEMBL11212968 0.79 RARB (0.69) RARBRARGRARACNR2ALDH1A1
SCHEMBL7793994 0.78 RXRA (0.47) RARBRARGRARAALDH1A1MAPK1
SCHEMBL20876246 0.78 BRD4 (0.47) BRD4RARBRARGRARACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319307-B2 2,3-dihydrobenzohurans as bromodomain inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2022-05-03 US disclosed
US-20200291009-A1 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2020-09-17 US disclosed
EP-3692036-A1 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2020-08-12 EP disclosed
WO-2019068782-A1 2,3-DIHYDROBENZOFURANS AS BOROMODOMAIN INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291009-A1 2,3-DIHYDROBENZOFURANS AS BROMODOMAIN INHIBITORS BRD4, BRPF3, BRD3 BRD4 1/4885RARB 2176/4885RARG 2707/4885
US-11319307-B2 2,3-dihydrobenzohurans as bromodomain inhibitors BRD4, BRD3, BRPF3 BRD4 1/4885RARB 1878/4885RARG 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.